This page is dedicated to Dermatology Times' independent editorial coverage of the American Academy of Dermatology Annual Meeting.
RUC ensures physician input on procedure codes
March 5th 2019As an expert on coding and office management, Mark D. Kaufmann, M.D., explained important role the AMA's Specialty Society Relative Value Update Committee (RUC) plays in code valuation during his presentation at the American Academy of Dermatology Annual Meeting in Washington, D.C.
New biologics target a number of dermatoses
March 3rd 2019The development of new biologics targeting a variety of dermatoses is on the upswing with some treatments coming to the clinic as early as this year, according to April Armstrong, M.D. who discussed the topic at the American Academy of Dermatology Spring Meeting in Washington, D.C.
Promising treatments in the pipeline for psoriasis
March 3rd 2019Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping. Andrew Blauvelt, M.D. discussed new drugs in the pipeline during American Academy of Dermatology Annual Meeting in Washington, D.C.
A look at the life cycle of drugs in dermatology
March 3rd 2019To help providers have a greater understanding of the efforts of the FDA to ensure all drugs are of pharmaceutical quality, Michael Kopcha, Ph.D., RPh, director of the FDA’s Office of Pharmaceutical Quality presented on the topic during the American Academy of Dermatology’s Annual Meeting in Washington, D.C.
Medical device regulation impacts patient care
March 2nd 2019Laura Marquart, M.D., FAAD, medical officer with the FDA’s Center for Devices and Radiological Health (CDRH), reviewed how the FDA approaches, reviews, and approves medical devices integral to dermatologic care at the American Academy of Dermatology’s annual meeting in Washington, D.C. Learn how this process can affect patient care in this article.
Standards are high for JAK inhibitors in psoriasis
March 2nd 2019While this new class of medications still has a role in treating psoriasis, this physician says the standard for both their efficacy and safety is very high because of the existing, already very effective systemic therapies available today.
Guidelines for managing skin disease during pregnancy
March 2nd 2019Treating chronic inflammatory skin conditions during pregnancy can be difficult because the therapies dermatologists prescribe can affect the unborn infant. See what insights this physician offers on managing chronic inflammatory skin conditions in pregnant patients.
Skin issues that affect patients with skin of color
February 6th 2019Healthcare disparities exist in all fields of medicine, including dermatology. We seek to address these disparities in this article by outlining the differences in epidemiology, presentation, access and outcomes of five conditions in patients with skin of color.